16th Congress Teaching Courses Streaming Content

16th International Congress Teaching Courses Streaming Content


Pricing: MDS Members: Free
Non- Members: $50 USD

The 16th International Congress Streaming Content includes the following sessions:

Session 2308: Update on psychogenic movement disorders

Chairs:
Mark Hallett
Bethesda, MD, USA
Jon Stone
Edinburgh, United Kingdom

Assessment of the patient with suspected PMD
Mark Edwards
London, United Kingdom

Approach to the patient: how to discuss the diagnosis with patients with PMD
Jon Stone
Edinburgh, United Kingdom

Management of PMD: Is this a treatable disorder
Karen Anderson
Baltimore, MD, USA

Learning Objectives
At the conclusion of this session, participants should be better able to:

  1. Recognize PMDs in patients
  2. Discuss diagnosis of PMDs with the patient
  3. Manage PMDs in patients

Recorded: June 18, 2012 (15:45-17:45)

Session 3309: Frontotemporal dementias and parkinsonism

Chairs:
Hugh Harrington
Cork, Ireland
Ian Mackenzie
Vancouver, BC, Canada

New advances in FTD genetics
Bryan Traynor
Bethesda, MD, SUA

The molecular basis of FTD
Ian Mackenzie
Vancouver, BC, Canada

Clinical overlap of FTD and parkinsonism
Zbigniew Wszolek
Jacksonville, FL, USA

Learning Objectives
At the conclusion of this session, participants should be better able to:

  1. Describe the relation of mutation in the C90RF72 gene on chromosome 9 with the FTD, ALS and parkinsonian phenotypic presentations
  2. Describe the heterogeneous molecular basis of FTD
  3. Discuss the overlap between FTD and parkinsonian syndromes

Recorded: June 19, 2012 (15:15-17:15) | *Also available on the 16th International Congress Themed Session DVD

Session 4307: Update on chorea

Chairs:
Oscar Gershanik
Buenos Aires, Argentina
Richard Walsh
Dublin, Ireland

Phenomenology and differential diagnosis
Oscar Gershanik Buenos Aires, Argentina

Non-genetic choreas
Mohit Bhatt Mumbai, India

Genetic choreas
Sarah Tabrizi London, United Kingdom

Learning Objectives
At the conclusion of this session, participants should be better able to:

  1. Identify choreic movements, differentiating it from other hyperkinetic movement disorders
  2. Recognize the most common genetic and non-genetic causes of chorea
  3. Manage motor and non-motor aspects of patients with choreic disorders

Recorded: June 20, 2012 (15:00-17:00)

Session 5307: Invasive therapies for advanced Parkinson's disease

Chairs:
Per Odin
Bermerhaven, Germany
Pierre Pollak
Geneva, Switzerland

Subcutaneous Apomorphine infusion
Erik Wolters
Amsterdam, Netherlands

Intestinal Levodopa infusion
Per Odin
Bremerhaven, Germany

Deep Brain Stimulation
Pierre Pollak
Geneva, Switzerland

Learning Objectives
At the conclusion of this session, participants should be better able to:

Recorded: June 21, 2012 (15:00-17:00)

  1. Describe the methodology and expected clinical effects of the invasive therapies
  2. Describe possible side effects and complications of the therapies
  3. Discuss patient selection for invasive therapies, based on indications and contraindications
Session 2309: Update on diagnosis and management of early parkinsonism

Chairs:
Shu-Leong Ho
Hong Kong
Timothy Lynch
Dublin, Ireland

Clinical characteristics of early parkinsonism and its differential diagnosis
Timothy Lynch
Dublin, Ireland

Neuroimaging techniques and other diagnostic procedures in the differential diagnosis of Parkinson’s disease
Christoph Scherfler
Innsbruck, Austria

Treatment of the early Parkinson’s disease patients
Shu-Leong Ho
Hong Kong

Learning Objectives
At the conclusion of this session, participants should be better able to:

  1. Describe the major features for Parkinson’s disease compared to red flags for atypical parkinsonism
  2. Determine essential diagnostic procedures and how meaningful they are
  3. Manage the start of treatment of Parkinson’s disease

Recorded: June 18, 2012 (15:45-17:45)

Session 3310: Update on levodopa-induced dyskinesias

Chairs:
Giovanni Fabbrini
Rome, Italy
Susan Fox
Toronto, ON, Canada

Pathophysiology of levodopa-induced dyskinesias
Susan Fox
Toronto, ON, Canada

Phenomenology, classification and assessment of levodopa-induced dyskinesias
Giovanni Fabbrini
Rome, Italy

Preventative and management strategies for levodopa-induced dyskinesias
Federico Micheli
Buenos Aires, Argentina

Learning Objectives
At the conclusion of this session, participants should be better able to:

  1. Understand the current concepts of the pathophysiology of levodopa-induced dyskinesias
  2. Be able to evaluate and assess patients with levodopa-induced dyskinesias
  3. Understand how to prevent and manage levodopa-induced dyskinesias

Recorded: June 19, 2012 (15:15-17:15)

Session 4308: Update on atypical parkinsonism

Chairs:
Fiona Molloy
Dublin, Ireland
Louis Tan
Singapore

 

Nosology of atypical parkinsonism
Roongroj Bhidayasiri
Bangkok, Thailand

Clinico-pathological correlation
Helen Ling
London, United Kingdom

Current treatment strategies for MSA, PSP and CBS
Maria Stamelou
Corinth, Greece

Learning Objectives
At the conclusion of this session, participants should be better able to:

  1. Recognize the key clinical features of MSA, PSP and CBS
  2. Review investigations that may help distinguish atypical parkinsonism
  3. Discuss management strategies for atypical parkinsonism

Recorded: June 19, 2012 (15:15-17:15)

Session 5308: The non-motor features of Parkinson’s disease

Chairs:
Angelo Antonini
Venice, Italy
K. Ray Chaudhuri
London, United Kingdom

Phenomenology of non-motor features in Parkinson's disease
K. Ray Chaudhuri
London, United Kingdom

How to assess the patient's non-motor complaints
Angelo Antonini
Rome, Italy

Treatment of non-motor symptoms: What is available?
Tove Henriksen
Copenhagen, Denmark

Learning Objectives
At the conclusion of this session, participants should be better able to:

Recorded: June 21, 2012 (15:00-17:00)

  1. Describe the different types of non-motor features of Parkinson's disease
  2. Evaluate the importance of non-motor features and asses their severity with validated tools
  3. Recognize the need of therapy for non-motor features and select appropriate medications
 

 

Top